Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.08)
# 3,521
Out of 4,829 analysts
80
Total ratings
34.94%
Success rate
-25.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $29.28 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.22 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.21 | - | 1 | Mar 14, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $170 → $200 | $155.24 | +28.83% | 17 | Feb 25, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $6.60 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.43 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $18.25 | - | 2 | Jan 13, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $6.04 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $0.71 | - | 7 | Nov 19, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.77 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.99 | +401.25% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.49 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.90 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.90 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.58 | +89.87% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $7.76 | +2,735.05% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.09 | +358.72% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.03 | +1,771.92% | 1 | Aug 12, 2022 |
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $29.28
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.22
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.21
Upside: -
Ascendis Pharma
Feb 25, 2025
Maintains: Overweight
Price Target: $170 → $200
Current: $155.24
Upside: +28.83%
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.60
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.43
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.25
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.04
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.71
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.77
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.99
Upside: +401.25%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.49
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.90
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.90
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.58
Upside: +89.87%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $7.76
Upside: +2,735.05%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.09
Upside: +358.72%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.03
Upside: +1,771.92%